Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06472830

MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study

This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. In some people, it slowly develops into a blood cancer called multiple myeloma. MGUS occurs in people from all backgrounds. Researchers hope to use the information from this study to improve knowledge, early detection, and future care for everyone.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Monoclonal Gammopathy of Undetermined Significance Blood Protein Disorders Hematologic Diseases Hemic and Lymphatic Diseases Hypergammaglobulinemia Immune System Diseases Immunoproliferative Disorders Paraproteinemias

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Mayo Clinic in Rochester

Rochester, Minnesota, 55905, United States

About this study

PRIMARY OBJECTIVE:

I. To determine the prevalence of monoclonal gammopathies (MGUS, Smoldering and Multiple Myeloma) across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.

OUTLINE: This is an observational study.

Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults ≥ 40 years
  • Willing and able to review, understand, and provide consent before starting any study-specific procedures
  • Ability to complete questionnaire(s) by themselves or with assistance

Exclusion criteria

  • Pregnant women

Treatment and study plan

Non-Interventional Study

Other

Non-interventional study

Primary outcomes

  1. Prevalence of monoclonal gammopathies across ancestrally diverse populations

    Time frame: Up to 10 years

    Screen for monoclonal gammopathies using mass spectrometry to detect monoclonal proteins among people across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Registry information

Official study title

Monoclonal Gammopathy of Undetermined Significance (MGUS) /Myeloma Awareness and Genetic Insights Campaign (MAGIC) Screening Study

Acronym: MAGIC

Important dates

Study start
2024
Primary completion
2029
Study completion
2029
First posted
Jun 25, 2024
Registry last updated
Mar 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.